参考文献/References:
[1] 徐风华, 郭荣荣, 李欣, 等. 非小细胞肺癌患者 ERCC1 表达与铂类药物化疗敏感性的相关性的系统分析[J]. 中国临床药理学与治疗学,2013, 18(1): 45-50.
[2] Zhu J, Cai L, Yang H, et al. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase rearrangement and epidermal growth factor receptor mutation coexisting in Chinese patients with lung adenocarcinoma[J]. Thoracic Cancer, 2014, 5(5): 411-416.
[3] 石远凯, 孙燕. 非小细胞肺癌分子靶向治疗的发展趋势[J]. 中华肿瘤杂志, 2014, 36(7): 481-484.
[4] Soda M,Choi Y L,Enomoto M,et a1.Identification of the transforming EMIA.ALK fusion geBe in non small cell lung cancer[J].Nature,2007,448(7153):561-566.
[5] Shaw A T,Yeap B Y,Mino-Kenudson M,et al.Clinical features and outcome of patients with non-small-cell lung cancer who harbor EMIA-ALK[J].J Clin Oncol,2009,27(26):4247-4253.
[6] 王丽杰,郭其森.EMIA-ALK融合基因——晚期非小细胞肺癌临床治疗新靶标[J].中华肺部疾病杂志:电子版,2014,7(1):94-97.
[7] Gridelli C,Solange P,Sgambato A,et al.ALK inhibitors in the treatment of advanced NSCLC[J].Cancer Treat Rev,2014,40(2):300-306.
[8] 朱翔,李红威,曹宝山,等.525例肺癌中ALK阳性病例临床病理特征研究及检测方法探讨[J].中国肺癌杂志,2014,17(3):226-232.
[9] Xia N,An J,Jiang Q Q.et al.Analysis of EGFR,EMIA-ALK,KRAS,and c-MET mutations in chinese lung adenocareinoma patients[J].Exp Lung Res,2013,39(8):328-335.
[10] 陈学敬,周立娟,董宇杰,等,Ventana全自动免疫组化法检测不同来源肺腺癌ALK蛋白表达一致性的研究 [J]. 诊断病理学杂志, 2016, 23(4): 259-262.
[11] 陈颖,高丽丽,王彦丽,等,间变性淋巴瘤激酶阳性肺腺癌细胞病理学特点初探[J].中华病理学杂志,2015,44(9):628-632.
[12] Solomon B J,Mok T,Kim D W,et al.First line erizotinib versus chemotherapy in ALK.positive lung cancer[J].N Engl J Med,2014,371(23):2167-2177.
[13] 杨红,王影,覃胜,等.浆膜腔积液细胞块对提高细胞学诊断及开展基因检测的价值[J].中华临床医师杂志:电子版,20l 3,7(21):9489-9493.
[14] 张旭超, 陆舜, 张力,等. 中国间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌诊断专家共识(2013版)[J]. 中华病理学杂志, 2013, 6(42): 402-406.
相似文献/References:
[1]陈新富 刘 宁 刘加夫.CK19在非小细胞肺癌淋巴结微转移中的检测价值(附90例分析)[J].福建医药杂志,2020,42(04):6.
CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(01):6.
[2]林 潇 陈愉生 李鸿茹.查尔森合并症指数及简化合并症评分对晚期非小细胞肺癌预后的影响[J].福建医药杂志,2020,42(05):23.
LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(01):23.
[3]李荣宾,黄延延,林贤宾,等.IGF1/RPI3K/Akt通路及其调控对非小细胞肺癌血管生成拟态形成影响的研究[J].福建医药杂志,2023,45(03):112.
[4]黄阳,陈静波,林贵山.动态监测循环肿瘤细胞对寡转移非小细胞肺癌联合治疗预后的价值[J].福建医药杂志,2023,45(05):8.
HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(01):8.
[5]钟颖,邹立,陈声池.EGFR T790M突变丰度对阿美替尼治疗晚期非小细胞肺癌疗效的影响[J].福建医药杂志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]